Trimetazidine
CARDIOVASCULAR SYSTEM
Also known as: kyurinett, trimetazidine dihydrochloride, trimetazidine HCl, trimetazidine hydrochloride, vastarel
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Trimetazidine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1978. DrugCentral lists 1 molecular target, including Cpt1b. Recorded indications include Angina pectoris.
- Molecular targets: Cpt1b (1 listed in DrugCentral).
- Indications: Angina pectoris.
- ATC code: C01EB15 (Other cardiac preparations).
- Molecular formula: C14H22N2O3; molecular weight 266.34 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Angina pectoris
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Carnitine O-palmitoyltransferase 1, muscle isoform | Cpt1b | unknown | IC50 5.89 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1978-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C01EB15 | CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › OTHER CARDIAC PREPARATIONS › Other cardiac preparations |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Cardiac failure | 300.6 |
| Rales | 178.2 |
| Dyspnoea at rest | 166.6 |
| Diastolic dysfunction | 165.7 |
| Tricuspid valve incompetence | 155.9 |
| Stenosis | 145.5 |
| Ejection fraction decreased | 145.5 |
| Pulmonary valve disease | 144.6 |
| Pericardial disease | 140.3 |
| Coronary artery stenosis | 126.6 |
| Ventricular hypokinesia | 124.1 |
| Angina pectoris | 123.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Trimetazidine is on its molecule page.
| Molecular formula | C14H22N2O3 |
|---|---|
| Molecular weight | 266.34 g/mol |
| CAS number | 5011-34-7 |
| InChIKey | UHWVSEOVJBQKBE-UHFFFAOYSA-N |
| PubChem CID | 21109 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Trimetazidine used for?
DrugCentral lists the following indications for Trimetazidine: Angina pectoris.
How does Trimetazidine work?
Its molecular targets in DrugCentral include Cpt1b.
When was Trimetazidine first approved?
Trimetazidine was first approved by the YEAR INTRODUCED in 1978.
What is the chemical formula of Trimetazidine?
Trimetazidine has the molecular formula C14H22N2O3 and a molecular weight of 266.34 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2750 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL203266 — compound record and bioactivity
- PubChem CID 21109 — chemical identifiers
- DrugBank DB09069 — drug record
- FDA UNII N9A0A0R9S8 — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.